Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Unknown 5Recruiting 3Completed 3Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 55Pancreatic Neoplasms 14Colorectal Neoplasms 6Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 4Biliary Tract Neoplasms 4Advanced Pancreatic Cancer 3Stage IV Gastric Cancer With Metastasis 2Recurrence 2Rectal Neoplasms 2Locally Advanced Pancreatic Cancer 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Gastric Cancer 2mCRC 1Surgically-Created Resection Cavity 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Non-small Cell Lung Cancer Stage â…¡ 1Nasopharyngeal Carcinoma 1NSCLC 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1HER2-positive 1HER-2 Negatived Gastric Cancer 1Gastric Cancer With Positive Exfoliative Cancer Cells 1

Interventions

Cisplatin 28Paclitaxel 19Radiotherapy 17Fluorouracil 13Drug Therapy 12camrelizumab 10toripalimab 8Carboplatin 8Radiation 7Capecitabine 7Radiotherapy, Intensity-Modulated 6sintilimab 5S 1 (combination) 5Esophagectomy 5tislelizumab 4nimotuzumab 4apatinib 4anlotinib 4Irinotecan 4Cetuximab 4Afatinib 4pembrolizumab 3durvalumab 3Vinorelbine 3Positron Emission Tomography Computed Tomography 3Oxaliplatin 3Nivolumab 3Immune Checkpoint Inhibitors 3Docetaxel 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Esophageal Squamous Cell Carcinoma × S 1 (combination) × Clear all
NCT05636150 2022-12-05

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Peking Union Medical College Hospital

Phase 2 Unknown
48 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03946969 2022-07-19

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02913066 2017-06-16

S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma

Mianyang Central Hospital

Phase 2 Unknown
88 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02677597 2016-02-09

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Fudan University

Phase 3 Unknown
268 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02586753 2015-10-26

Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus

Mianyang Central Hospital

Phase 2 Unknown
2 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡